Nasdaq · Healthcare
PROTHENA CORP PUBLIC LTD CO (PRTA)
As-reported financials and recent SEC filings for PROTHENA CORP PUBLIC LTD CO, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$9.7M
Net income
$-244.1M
Net margin
—
Diluted EPS
$-4.53
ROE
-87.0%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $9.7M | $135.2M | $91.4M | $53.9M | $200.6M |
| Gross profit | — | — | — | — | — |
| Operating income | $-214.6M | $-154.6M | $-191.0M | $-131.6M | $72.0M |
| Net income | $-244.1M | $-122.3M | $-147.0M | $-116.9M | $67.0M |
| Diluted EPS | $-4.53 | $-2.27 | $-2.76 | $-2.47 | $1.38 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-18
View on EDGAR →42026-06-16
View on EDGAR →42026-06-12
View on EDGAR →32026-06-12
View on EDGAR →1442026-06-09
View on EDGAR →42026-06-05
View on EDGAR →42026-06-03
View on EDGAR →42026-05-26
View on EDGAR →Largest Healthcare peers
Go deeper on PRTA
Search PROTHENA CORP PUBLIC LTD CO’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.